Annals of Medicine and Medical Sciences (AMMS)
Volume 05, 2026, *Page No.: 267 to 272*
Available at: *http://ammspub.com*

Systematic Review

OPEN ACCESS

Blinatumomab for Minimal Residual Disease Clearance in B-Acute Lymphoblastic Leukemia

Dr. Suhena Sarkar, MD [1], Birupaksha Biswas, MD [2]

[1]Associate Professor, Department of Pharmacology, Medical College Kolkata, Kolkata, West Bengal, India.
[2]Senior Resident, Department of Pathology, Burdwan Medical College and Hospital, Kolkata, India.

*Corresponding Author: Dr. Birupaksha Biswas, MD; *drbiswasmd@aol.com*

Abstract

Objective: To evaluate the efficacy, safety, and clinical impact of blinatumomab across the treatment continuum of B-cell acute lymphoblastic leukemia. ***Design:*** Systematic evidence synthesis of randomized clinical trials and comparative cohort studies. ***Subjects/Patients:*** Children, adolescents, and adults with newly diagnosed, relapsed or refractory, or minimal residual disease–positive B-cell acute lymphoblastic leukemia. ***Methods:*** This systematic review followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed, PubMed Central, and ClinicalTrials.gov were searched from January 2010 through December 2025. Comparative randomized and observational studies evaluating blinatumomab versus chemotherapy were included. Data on survival, remission, minimal residual disease clearance, adverse events, and transplantation outcomes were qualitatively synthesized. ***Results:*** Blinatumomab significantly improved overall survival and complete remission rates compared with chemotherapy in relapsed or refractory disease. Minimal residual disease clearance occurred at higher frequencies and was consistently associated with improved long-term survival. Integration into consolidation and frontline therapy reduced relapse risk and enhanced transplantation eligibility. Treatment-related myelosuppression was lower than with chemotherapy, although immune-mediated adverse events were observed. ***Conclusion:*** Blinatumomab provides durable molecular remission, survival advantage, and improved tolerability, supporting its integration across multiple treatment phases of B-cell acute lymphoblastic leukemia.

Keywords: ***Acute Lymphoblastic Leukemia, Blinatumomab, Immunotherapy, Minimal Residual Disease, Survival Analysis.***

Introduction

Acute lymphoblastic leukemia (ALL) is an aggressive hematologic malignancy characterized by clonal proliferation of immature lymphoid precursors within the bone marrow, peripheral blood, and extramedullary compartments. The disease demonstrates marked biological heterogeneity driven by age, immunophenotype, cytogenetic architecture, molecular alterations, and host immune competence [21,22]. Although contemporary multiagent chemotherapy induces high rates of complete remission, particularly in pediatric populations, survival declines sharply with advancing age, adverse genomic features, and persistence of minimal residual disease (MRD) [9,17,23]. Outcomes after relapse remain poor, with historical salvage regimens yielding limited remission durability and substantial treatment-related morbidity [9,10]. Intensified cytotoxic strategies such as hyper-CVAD improved initial responses but did not fundamentally alter the adverse prognosis of relapsed disease [11].

Advanced ALL, encompassing relapsed or refractory disease and high-risk molecular subsets, therefore remains a critical unmet need. Conventional salvage chemotherapy is constrained by cumulative myelosuppression, infectious complications, organ toxicity, and transplant ineligibility [10,23]. These limitations have accelerated the transition toward immune-based therapeutics designed to deliver deeper remissions with improved therapeutic index.

MRD has emerged as a dominant prognostic biomarker in ALL. Standardized detection methodologies confirm that MRD positivity after induction or consolidation independently predicts early relapse and inferior survival across age groups [13,14]. Therapeutic paradigms have consequently shifted from achieving morphologic remission alone to eradicating subclinical leukemic burden [15]. Chemotherapy intensification rarely overcomes persistent MRD and frequently amplifies toxicity, particularly in older adults [20]. This biological insight provided the rationale for targeted immunotherapies capable of eliminating residual leukemic clones.

Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct that simultaneously targets CD19 on B-cell precursors and CD3 on cytotoxic T lymphocytes, inducing direct immune synapse formation and T-cell–mediated cytolysis independent of major histocompatibility complex presentation [16,19]. Early-phase studies demonstrated substantial complete remission and MRD-negativity rates in relapsed or refractory B-cell precursor ALL, establishing proof of concept for immune redirection [12,16].

The pivotal phase III TOWER trial (NCT02013167) demonstrated superior overall survival with blinatumomab compared with standard chemotherapy in adults with relapsed or refractory ALL, thereby redefining salvage therapy standards [1,8]. Subsequent analyses confirmed a favorable exposure-adjusted safety profile relative to chemotherapy [2]. In pediatric high-risk first

Received: February 04, 2026; **Revised:** February 25, 2026; **Accepted:** February 28, 2026

relapse, randomized evidence similarly showed improved event-free survival with blinatumomab [3]. More recently, incorporation of blinatumomab into consolidation and frontline regimens has reduced recurrence risk in both adult and pediatric populations, including patients who achieved MRD-negative status after induction [5-7]. Real-world cohort data further corroborate its capacity to eradicate MRD in diverse clinical settings [4].

Collectively, these findings position blinatumomab at the forefront of immune-directed therapy in ALL. However, the magnitude, consistency, and clinical applicability of its benefit relative to conventional chemotherapy across disease states require rigorous synthesis. This systematic review therefore critically evaluates comparative outcomes of blinatumomab versus chemotherapy in advanced ALL, with emphasis on survival, MRD eradication, relapse prevention, safety, and integration into contemporary treatment algorithms.

Methods

This systematic review was conducted in accordance with the 2020 update of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement. The methodology encompassed structured processes for study identification, screening, eligibility assessment, data extraction, and qualitative synthesis.

Search Strategy

A comprehensive literature search was performed in PubMed, PubMed Central, and ClinicalTrials.gov to identify relevant studies published between January 2010 and December 2025. The search timeframe was selected to capture contemporary trials reflecting modern treatment paradigms in acute lymphoblastic leukemia.

The search strategy combined controlled vocabulary and keyword-based queries. Core search terms included:

“blinatumomab AND chemotherapy AND acute lymphoblastic leukemia”,
“blinatumomab versus chemotherapy ALL”,
“phase III blinatumomab trial ALL”, and
“blinatumomab minimal residual disease ALL”.

Filters were applied for human studies, clinical trials, randomized controlled trials, and open-access publications where available. Reference lists of eligible studies were manually screened to identify additional relevant articles.

Inclusion and Exclusion Criteria

Studies were eligible if they met the following criteria:

1. *Population:* Pediatric, adolescent, or adult patients with B-cell acute lymphoblastic leukemia in relapsed/refractory, minimal residual disease–positive, consolidation, or frontline settings.
2. *Intervention:* Blinatumomab-based therapy.
3. *Comparator:* Conventional chemotherapy or standard-of-care regimens.
4. *Study design:* Randomized controlled trials, comparative cohort studies (including propensity-matched analyses), or meta-analyses of randomized trials.
5. *Outcomes:* Reported at least one clinically relevant endpoint, including survival, remission rates, minimal residual disease clearance, relapse incidence, transplantation rates, or adverse events.

Exclusion criteria included non-comparative single-arm studies without contextual comparison, preclinical or animal studies, review articles, editorials, conference abstracts lacking full data, and studies not reporting extractable efficacy or safety outcomes.

Study Selection Process

All identified records were imported into a screening framework. Duplicate entries were removed prior to review. Titles and abstracts were screened independently for relevance. Full-text articles of potentially eligible studies were assessed against predefined inclusion criteria. Disagreements during screening were resolved through discussion and consensus.

A total of 327 records were identified. After removal of 94 duplicates, 233 unique records underwent title and abstract screening. Of these, 189 were excluded for irrelevance, absence of comparative data, or non-clinical design. Forty-four full-text articles were assessed for eligibility, and 34 were excluded due to lack of direct comparison with chemotherapy, insufficient outcome reporting, or restricted access. Ten studies met all inclusion criteria and were included in the final qualitative synthesis. The selection process is illustrated in Figure 1.



Fig. 1: The figure illustrates the systematic process of study identification screening eligibility assessment and inclusion conducted in accordance with PRISMA 2020 guidelines. A total of 327 records were identified through database searching of PubMed and PubMed Central. After removal of 94 duplicate records 233 unique records underwent title and abstract screening. Of these 189 records were excluded due to irrelevance to the research question non comparative design or non clinical study type. Full text assessment for eligibility was performed for 44 reports of which 34 were excluded because they lacked a direct comparison with chemotherapy did not report key efficacy or safety outcomes or had restricted access. Ultimately 10 studies met all predefined inclusion criteria and were included in the final qualitative synthesis.

Data Extraction

Data extraction was performed independently by two reviewers using a predefined structured template. Extracted variables included:

1. Study design and setting
2. Patient population characteristics
3. Treatment regimens and comparator arms
4. Survival outcomes (overall survival, disease-free survival, event-free survival)
5. Complete remission rates
6. Minimal residual disease negativity rates
7. Relapse incidence
8. Rates of allogeneic hematopoietic stem cell transplantation
9. Adverse events and treatment-related mortality

Discrepancies were resolved by consensus review.

Outcome Measures

The primary endpoints were overall survival and disease-free survival or event-free survival.

Secondary endpoints included complete remission rates, minimal residual disease negativity, cumulative incidence of relapse, progression-free survival metrics, rates of allogeneic hematopoietic stem cell transplantation, and treatment-related adverse events.

Quality Assessment and Analysis Approach

Methodological quality and risk of bias were assessed qualitatively, with emphasis on study design, randomization methodology, comparator integrity, and clinical relevance of reported endpoints. Given heterogeneity in study populations, disease settings, and outcome reporting, a quantitative meta-analysis was not performed. Instead, findings were synthesized descriptively to provide a structured comparative evaluation of efficacy and safety across clinical contexts.

Ethical Considerations and Trial Registration

As this study represents a secondary analysis of previously published data, ethical clearance and patient consent were not required. Trial registration was not applicable.

Results

Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Across the included comparative studies, blinatumomab demonstrated consistent superiority over conventional chemotherapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The pivotal phase III TOWER trial established a statistically significant overall survival benefit, with median survival of 7.7 months in the blinatumomab arm versus 4.0 months in the chemotherapy arm, corresponding to a hazard ratio for

death of 0.71 [1]. This survival advantage was accompanied by higher complete remission rates and prolonged remission duration.

Importantly, improved survival was paralleled by greater depth of response. Higher rates of minimal residual disease (MRD) negativity were observed among responders, which is clinically meaningful given the strong prognostic association between MRD clearance and long-term outcome [12,14]. Furthermore, a greater proportion of patients treated with blinatumomab proceeded to potentially curative allogeneic hematopoietic stem cell transplantation compared with those receiving salvage chemotherapy [1].

The safety profile was further clarified in exposure-adjusted analyses demonstrating lower rates of severe hematologic toxicity relative to chemotherapy, reflecting reduced cumulative myelosuppression [2]. These findings are particularly relevant in heavily pretreated populations, where treatment-related cytopenias often limit therapeutic intensity.

Pediatric and Young Adult Relapsed Disease

In pediatric and young adult populations with high-risk first relapse, randomized comparative data likewise favored blinatumomab. The trial conducted by Locatelli and colleagues demonstrated superior event-free survival with blinatumomab compared with intensive chemotherapy, alongside significantly higher MRD negativity rates [3]. Notably, treatment-related toxicity and severe infectious complications were reduced, underscoring both efficacy and tolerability in this vulnerable population.

Real-world multicenter cohort data further corroborated the capacity of blinatumomab to eradicate MRD in pediatric patients with persistent molecular disease or delayed chemotherapy, with high response rates even in relapsed or refractory settings [4]. These findings reinforce the robustness of MRD-directed immunotherapy beyond strictly controlled trial environments.

MRD-Directed and Consolidation Strategies in Adults

The prognostic centrality of MRD in ALL is well established, with meta-analytic evidence demonstrating that MRD positivity independently predicts relapse and inferior survival across age groups [14]. Consequently, therapeutic strategies capable of achieving molecular remission are of critical importance.

In adults with MRD-negative disease following induction, the E1910 study demonstrated that incorporation of blinatumomab into consolidation therapy significantly improved three-year overall survival compared with chemotherapy alone [5]. This trial provides high-level evidence that early integration of immunotherapy enhances durability of remission even in patients who have already achieved morphologic response.

Long-term follow-up analyses of MRD responders treated with blinatumomab in earlier phase studies have further shown durable survival and sustained molecular remission, particularly when consolidated with transplantation [12]. Collectively, these data confirm that blinatumomab not only induces remission but deepens it at the molecular level, translating into clinically meaningful survival gains.

Frontline Pediatric Integration

The therapeutic benefit of blinatumomab has extended into frontline pediatric therapy. In standard-risk B-cell ALL, incorporation of blinatumomab into chemotherapy regimens significantly improved disease-free survival and reduced recurrence risk [6]. Independent commentary and secondary analyses have emphasized that these gains were achieved without increasing overall toxicity burden, suggesting that immunotherapy may enable refinement and potential de-escalation of cytotoxic exposure in selected patients [7].

The ability to integrate blinatumomab earlier in treatment paradigms reflects a broader evolution in ALL management, shifting from purely cytotoxic intensification toward biologically targeted, response-adapted therapy [19,26].

Comparative Therapeutic Context and Historical Controls

The magnitude of benefit observed with blinatumomab must be interpreted against historical outcomes with salvage chemotherapy. Prior cooperative group analyses consistently reported low complete remission rates and poor median survival following relapse, often not exceeding six to eight months in multiply treated adults [9,10,17,23]. Intensive regimens such as hyper-CVAD improved frontline outcomes but did not meaningfully overcome the adverse prognosis associated with relapse [11].

In this context, the hazard ratio of 0.71 observed in the TOWER trial represents a clinically substantive shift in therapeutic expectation [1]. Moreover, the reduced incidence of severe cytopenias compared with chemotherapy [2] enhances feasibility in older adults and medically fragile populations, groups historically characterized by inferior tolerance and outcomes [20,21].

Safety Profile and Immune-Mediated Toxicity

Although blinatumomab reduces myelosuppressive toxicity relative to conventional chemotherapy, it is associated with distinct immune-mediated adverse events. Cytokine release syndrome and neurologic toxicity were observed in both early-phase and randomized trials, but these events were generally manageable with stepwise dosing strategies, vigilant monitoring, and supportive care algorithms [16].

Mechanistically, such toxicities reflect the agent's bispecific T-cell–engaging activity, which facilitates rapid immune synapse formation and cytotoxic activation [19]. Importantly, exposure-adjusted analyses indicate that overall treatment-related mortality remains lower than with intensive salvage chemotherapy [2].

Summary of Efficacy Across Clinical Settings

Taken together, the evidence demonstrates that blinatumomab improves overall survival, event-free survival, MRD eradication rates, and transplantation eligibility across relapsed, consolidation, and frontline settings in both adult and pediatric B-cell ALL. The consistency of benefit across randomized trials, multicenter cohorts, and long-term follow-up studies underscores the reproducibility and clinical robustness of its therapeutic effect.

These results collectively establish blinatumomab as a central component of contemporary ALL management, with its greatest impact mediated through deep molecular remission, improved survival probability, and reduced cytotoxic burden.

Discussion

Therapeutic Reframing of Relapsed and Refractory Disease

The management of B-cell acute lymphoblastic leukemia (ALL) has shifted from reliance on intensified cytotoxic chemotherapy toward immune-mediated precision strategies. Historically, adults with relapsed or refractory disease experienced poor outcomes, with low remission rates and median survival rarely exceeding six months after salvage therapy [9,10,17,23]. Although regimens such as hyper-CVAD improved frontline responses, they did not meaningfully overcome the adverse biology of relapse [11].

The phase III trial by Hagop Kantarjian and colleagues established blinatumomab as the first immunotherapy to demonstrate a statistically significant overall survival advantage over chemotherapy in this setting [1]. This finding redefined expectations for salvage therapy and positioned immune engagement as a viable survival-modifying strategy.

Depth of Response and MRD as a Therapeutic Endpoint

Minimal residual disease (MRD) has emerged as a dominant prognostic determinant in ALL. Meta-analytic data confirm that MRD positivity independently predicts relapse and inferior survival across age groups [14]. Standardization of MRD assessment techniques has further enabled response-adapted therapeutic strategies [13,15].

Blinatumomab consistently achieves high rates of MRD eradication, including in patients with morphologic remission but molecular persistence [12]. In the E1910 study, incorporation of blinatumomab into consolidation improved survival even among patients who were MRD-negative after induction, underscoring the additive value of immune-based consolidation [5]. Collectively, these data support MRD clearance not merely as a surrogate marker but as a therapeutic objective central to durable remission.

Pediatric Integration and Early-Line Therapy

In pediatric relapse, randomized evidence demonstrated superior event-free survival and improved tolerability with blinatumomab compared with chemotherapy [3]. Subsequent frontline integration in standard-risk disease further reduced recurrence risk without excess toxicity [6,7]. Real-world data confirm robust MRD clearance in diverse pediatric settings [4].

These findings suggest that immunotherapy can be safely introduced earlier in the disease course, potentially enabling de-escalation of cumulative cytotoxic exposure while preserving survival outcomes.

Safety and Comparative Positioning

A key advantage of blinatumomab lies in its toxicity profile. Exposure-adjusted analyses demonstrate reduced severe myelosuppression compared with chemotherapy [2]. Although cytokine release syndrome and neurologic events occur, they are generally manageable with established mitigation strategies, as shown in early-phase evaluations [16].

When positioned against other CD19-directed approaches, blinatumomab occupies a distinct niche. Unlike chimeric antigen receptor T-cell therapy, it does not require individualized cellular manufacturing or prolonged hospitalization [24]. Compared with inotuzumab ozogamicin, it carries a lower risk of hepatotoxicity and veno-occlusive complications, particularly relevant in transplant candidates [25]. This balance of efficacy, safety, and logistical feasibility enhances its applicability across treatment settings.

Special Populations and Therapeutic Equity

Older adults remain a high-risk cohort due to comorbidity burden and intolerance to intensive chemotherapy [20,21]. By reducing myelosuppressive toxicity while preserving efficacy, blinatumomab expands therapeutic access for patients historically excluded from aggressive regimens. This shift has implications for improving outcome equity across age groups.

Resistance and Future Directions

Despite durable responses, resistance remains a challenge. Mechanisms include antigen modulation, impaired T-cell function, and microenvironmental immune suppression [18]. Ongoing research focuses on optimizing sequencing, combining immune platforms, and refining biomarker-driven selection strategies [19,26].

The broader significance of blinatumomab lies in its validation of bispecific T-cell engagement as a therapeutic paradigm. Its clinical success has catalyzed development of next-generation constructs and combinatorial immunotherapy approaches, signaling a sustained transition toward immune-centric leukemia management.

Conclusion

In conclusion, convergent evidence from randomized trials and contemporary cohort analyses establishes blinatumomab as a foundational therapy in B-cell acute lymphoblastic leukemia. It confers a reproducible survival advantage in relapsed or refractory disease, achieves high rates of minimal residual disease clearance, and reduces treatment-related myelosuppression relative to chemotherapy. Its integration into MRD-guided consolidation and frontline strategies signals a paradigm shift toward response-adapted immunotherapy. Future progress will depend on biomarker-driven patient selection, rational sequencing with cellular and antibody–drug conjugate platforms, resistance mitigation strategies targeting CD19 modulation and T-cell exhaustion, and standardized MRD harmonization. These advances collectively aim to convert molecular remission into durable cure across age and risk strata.

Declarations

Conflict of interest

None

Funding/ financial support

None

Ethical Clearance

Not Applicable

Trial details

Not Applicable

References

[1] Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017;376(9):836-847. doi:10.1056/NEJMoa1609783

[2] Stein AS, Larson RA, Schuh AC, et al. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018;2(13):1522-1531. doi:10.1182/bloodadvances.2018019034

[3] Locatelli F, Zugmaier G, Rizzari C, et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. JAMA. 2021;325(9):843-854. doi:10.1001/jama.2021.0987

[4] Zhang N, Hu W, Dai Y, et al. Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study. Front Immunol. 2025;16:1607138. Published 2025 Sep 18. doi:10.3389/fimmu.2025.1607138

[5] Litzow MR, Sun Z, Mattison RJ, et al. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024;391(4):320-333. doi:10.1056/NEJMoa2312948

[6] Gupta S, Rau RE, Kairalla JA, et al. Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in

Children. N Engl J Med. 2025;392(9):875-891. doi:10.1056/NEJMoa2411680

[7] Sidaway, P. Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL. Nat Rev Clin Oncol 22, 79 (2025). https://doi.org/10.1038/s41571-024-00980-1

[8] ClinicalTrials.gov entry NCT02013167: Blinatumomab versus SOC chemotherapy in relapsed/refractory ALL (TOWER trial details), https://clinicaltrials.gov/study/NCT02013167

[9] O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer. 2008;113(11):3186-3191. doi:10.1002/cncr.23919

[10] Gökbuget N, Dombret H, Ribera JM, et al. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016;101(12):1524-1533. doi:10.3324/haematol.2016.144311

[11] Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18(3):547-561. doi:10.1200/JCO.2000.18.3.547

[12] Zugmaier G, Gökbuget N, Klinger M, et al. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment. Blood. 2015;126(24):2578-2584. doi:10.1182/blood-2015-06-649111

[13] Ikoma-Colturato MRV, Beltrame MP, Furtado FM, et al. Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation. Hematol Transfus Cell Ther. 2021;43(3):332-340. doi:10.1016/j.htct.2020.09.148

[14] Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual Disease with Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol. 2017;3(7):e170580. doi:10.1001/jamaoncol.2017.0580

[15] Short NJ, Jabbour E. Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It. Curr Oncol Rep. 2017;19(1):6. doi:10.1007/s11912-017-0565-x

[16] Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57-66. doi:10.1016/S1470-2045(14)71170-2

[17] Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944-950. doi:10.1182/blood-2006-05-018192

[18] Schultz L, Gardner R. Mechanisms of and approaches to overcoming resistance to immunotherapy. Hematology Am Soc Hematol Educ Program. 2019;2019(1):226-232. doi:10.1182/hematology.2019000018

[19] Jabbour E, Kantarjian H. Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies. Blood Adv. 2016;1(3):260-264. Published 2016 Dec 27. doi:10.1182/bloodadvances.2016000042

[20] Aldoss I, Forman SJ, Pullarkat V. Acute Lymphoblastic Leukemia in the Older Adult. J Oncol Pract. 2019;15(2):67-75. doi:10.1200/JOP.18.00271

[21] Paul S, Kantarjian H, Jabbour EJ. Adult Acute Lymphoblastic Leukemia. Mayo Clin Proc. 2016;91(11):1645-1666. doi:10.1016/j.mayocp.2016.09.010

[22] Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. Published 2017 Jun 30. doi:10.1038/bcj.2017.53

[23] Gökbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-2041. doi:10.1182/blood-2011-12-399287

[24] Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45-55. doi:10.1016/j.blre.2018.11.002

[25] Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125(14):2474-2487. doi:10.1002/cncr.32116

[26] Samra B, Jabbour E, Ravandi F, Kantarjian H, Short NJ. Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions. J Hematol Oncol. 2020;13(1):70. Published 2020 Jun 5. doi:10.1186/s13045-020-00905-2

[27] Haddaway, N. R., Page, M. J., Pritchard, C. C., & McGuinness, L. A. (2022). PRISMA2020: An R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis Campbell Systematic Reviews, 18, e1230. https://doi.org/10.1002/cl2.1230